Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease

NCT00137332

Last updated date
Study Location
Sacramento, California, 95819, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Arrhythmia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with or without ICDs (implantable cardioverter defibrillators)

- Patients undergoing an electrophysiology study for evaluation of ventricular rhythm

- Patients with a history of heart disease

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients with uncontrolled blood pressure


- Patients with certain cardiac risk factors


- Patients with significant kidney or liver problems

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

ArrhythmiaStudy Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease
NCT00137332
  1. Sacramento, California
  2. San Francisco, California
  3. Washington, District of Columbia
  4. Orlando, Florida
  5. Peoria, Illinois
  6. Iowa City, Iowa
  7. Worcester, Massachusetts
  8. Ann Arbor, Michigan
  9. Lansing, Michigan
  10. Southfield, Michigan
  11. Minneapolis, Minnesota
  12. Newark, New Jersey
  13. Winston-Salem, North Carolina
  14. Cleveland, Ohio
  15. Cleveland, Ohio
  16. Hershey, Pennsylvania
  17. Wynnewood, Pennsylvania
  18. Falls Church, Virginia
  19. Norfolk, Virginia
  20. Edmonton, Alberta
  21. Vancouver, British Columbia
  22. Victoria, British Columbia
  23. St-Johnâ s, Newfoundland and Labrador
  24. Halifax, Nova Scotia
  25. London, Ontario
  26. Newmarket, Ontario
  27. Toronto, Ontario
  28. Fleurimont, Quebec
  29. Montreal, Quebec
  30. Montreal, Quebec
  31. Montreal, Quebec
  32. Sainte-Foy, Quebec
  33. Sherbrooke, Quebec
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ArrhythmiaSingle Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously
NCT00510029
  1. Philadelphia, Pennsylvania
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ArrhythmiaStudy Evaluating GAP-486 in Heart Rhythm
NCT00137293
  1. San Francisco, California
  2. Washington, District of Columbia
  3. Hershey, Pennsylvania
  4. Ottawa, Ontario
  5. Toronto, Ontario
  6. Montreal, Quebec
  7. Montreal, Quebec
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ArrhythmiaAtorvastatin For The Reduction Of Ventricular Arrhythmias
NCT00457340
  1. Aalst,
  2. Antwerpen,
  3. Brugge,
  4. Edegem,
  5. Gent,
  6. Hasselt,
  7. Leuven,
  8. Athens,
  9. Crete,
  10. Rio Patra,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease
Official Title  ICMJE A Study of the Effects GAP-486 on Ventricular Tachyarrhythmia Induction
Brief Summary The purpose of this study is to learn the effects of a test drug on heart rhythms, which may become life-threatening if left untreated, and to provide data to see if the drug is well tolerated and safe.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Arrhythmia
Intervention  ICMJE
  • Drug: GAP-486 (ZP-123)
  • Drug: 0.9% Sodium Chloride, USP
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Enrollment  ICMJE
 (submitted: August 25, 2005)
90
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE October 2006
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients with or without ICDs (implantable cardioverter defibrillators)
  • Patients undergoing an electrophysiology study for evaluation of ventricular rhythm
  • Patients with a history of heart disease

Exclusion Criteria:

  • Patients with uncontrolled blood pressure
  • Patients with certain cardiac risk factors
  • Patients with significant kidney or liver problems
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00137332
Other Study ID Numbers  ICMJE 3163K1-202
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP